10-K: Mereo BioPharma Group plc Details Securities Registered Under the Exchange Act

Mereo BioPharma Group plc provides a description of its ordinary shares and American Depositary Shares (ADSs) registered under the Securities Exchange Act of 1934.

Summary

• Mereo BioPharma Group plc, incorporated in England and Wales, has registered its ordinary shares, represented by American Depositary Shares (ADSs), under Section 12 of the Securities Exchange Act of 1934.
• Each ADS represents five ordinary shares with a par value of 0.003 per share.
• The company was originally incorporated as a private limited company on March 10, 2015, and re-registered as a public limited company on June 3, 2016.
• Shareholders are entitled to one vote per ordinary share, receive notice of general meetings, and are eligible for dividends as recommended by the directors and declared by the shareholders.
• The company maintains a share register, which is the primary evidence of share ownership, but this register does not typically disclose the ultimate beneficial owners of the shares.
• ADS holders are not treated as shareholders in the share register; instead, the depositary or its nominees are the registered holders of the underlying ordinary shares.
• The company is required to update the share register within two months of any share allotment or transfer.
• English law provides shareholders with preemptive rights when new shares are issued for cash, but these rights can be excluded by the company's articles of association or by a special resolution of shareholders.
• The company's articles of association state that the objects of the company are unrestricted and shares may be issued with any rights or restrictions as determined by the shareholders or the board.
• Voting rights are one vote per shareholder on a show of hands and one vote per share on a poll.
• Dividends are declared by shareholders based on the directors' recommendations and are paid according to the amounts paid up on the shares.
• There are no specific provisions in the articles of association that would delay, defer, or prevent a change of control.
• In the event of liquidation, the liquidator may distribute assets among shareholders, subject to shareholder authorization.
• Shareholder rights can be varied with the consent of at least three-fourths of the issued shares of that class or by special resolution.
• The company may consolidate or subdivide its share capital by ordinary resolution and reduce its share capital by special resolution confirmed by the court.
• Shareholders may have statutory preemption rights when new shares are issued for cash.
• The board may decline to register a share transfer under certain conditions, such as if the shares are not fully paid or if the transfer is not properly lodged.
• The company is required to hold an annual general meeting each year, with 21 days' notice for the annual meeting and 14 days' notice for other general meetings.
• A quorum for general meetings is at least two shareholders present in person or by proxy, or at least 33 1/3% of the issued and outstanding ordinary shares if required by a securities exchange.
• The board of directors must have at least two and no more than ten directors, with the number variable by ordinary resolution of the shareholders.
• Directors appointed by the board hold office until the next annual general meeting and must retire at the third annual general meeting following their election.
• Under the U.K. Companies Act 2006, an offeror who has acquired 90% of the shares may compulsorily acquire the remaining shares.
• Minority shareholders have the right to be bought out by an offeror who has acquired 90% of the voting shares.
• The company is empowered to require disclosure of interest in shares and may restrict voting rights or dividend payments for non-compliance.
• The company may purchase its own shares out of distributable profits or the proceeds of a fresh issue of shares, subject to certain conditions.
• The company must have sufficient distributable reserves and net assets to make a distribution or dividend.
• The U.K. City Code on Takeovers and Mergers does not currently apply to the company, but may in the future if the majority of directors are resident in the U.K., Channel Islands, or the Isle of Man.
• There are no governmental laws in the U.K. that affect the import or export of capital or the remittance of dividends to non-residents.
• Citibank, N.A. acts as the depositary for the ADSs, with each ADS representing five ordinary shares.
• ADS holders have the right to receive the ordinary shares underlying their ADSs and to exercise beneficial ownership interests through the depositary.
• The deposit agreement and ADRs are governed by New York law, while the company's obligations to ordinary shareholders are governed by the laws of England and Wales.
• ADS holders can exercise shareholder rights through the depositary to the extent contemplated in the deposit agreement.
• ADS holders may hold their ADSs through an ADR, a brokerage account, or the direct registration system (DRS).
• The depositary will distribute cash, shares, or rights to subscribe for additional shares to ADS holders, subject to fees, taxes, and expenses.
• The depositary may sell undistributed rights or property and distribute the proceeds to ADS holders.
• ADS holders may have to pay fees, expenses, taxes, and other governmental charges upon the redemption of their ADSs.
• The depositary may amend the deposit agreement without the consent of ADS holders, but must provide 30 days' notice for modifications that materially prejudice their rights.
• The depositary may terminate the deposit agreement with 30 days' notice to ADS holders.
• The depositary maintains ADS holder records in New York and provides facilities for processing ADS transactions.
• The deposit agreement limits the obligations and liabilities of the company and the depositary.
• ADS holders are responsible for taxes and governmental charges on ADSs and the underlying securities.
• The depositary will convert foreign currency into U.S. dollars for distribution to ADS holders.
• The deposit agreement and ADRs are interpreted in accordance with the laws of the State of New York, and ADS holders waive their right to a jury trial in any legal proceeding against the company or the depositary.

Sentiment

Score: 7

Explanation: The document is factual and descriptive, outlining the legal and structural aspects of the company's securities. It does not contain any information that would be considered positive or negative from an investment perspective, but it is important for investors to understand the rights and obligations associated with owning the company's shares or ADSs.

Positives

• Shareholders are entitled to one vote per ordinary share, receive notice of general meetings, and are eligible for dividends as recommended by the directors and declared by the shareholders.
• The company is required to update the share register within two months of any share allotment or transfer.
• The company may consolidate or subdivide its share capital by ordinary resolution and reduce its share capital by special resolution confirmed by the court.
• Minority shareholders have the right to be bought out by an offeror who has acquired 90% of the voting shares.
• There are no governmental laws in the U.K. that affect the import or export of capital or the remittance of dividends to non-residents.
• ADS holders have the right to receive the ordinary shares underlying their ADSs and to exercise beneficial ownership interests through the depositary.
• The depositary will convert foreign currency into U.S. dollars for distribution to ADS holders.

Negatives

• The company's share register does not typically disclose the ultimate beneficial owners of the shares.
• ADS holders are not treated as shareholders in the share register; instead, the depositary or its nominees are the registered holders of the underlying ordinary shares.
• English law provides shareholders with preemptive rights when new shares are issued for cash, but these rights can be excluded by the company's articles of association or by a special resolution of shareholders.
• There are no specific provisions in the articles of association that would delay, defer, or prevent a change of control.
• The U.K. City Code on Takeovers and Mergers does not currently apply to the company, but may in the future if the majority of directors are resident in the U.K., Channel Islands, or the Isle of Man.
• ADS holders can exercise shareholder rights through the depositary to the extent contemplated in the deposit agreement.
• ADS holders may have to pay fees, expenses, taxes, and other governmental charges upon the redemption of their ADSs.
• The deposit agreement limits the obligations and liabilities of the company and the depositary.
• ADS holders are responsible for taxes and governmental charges on ADSs and the underlying securities.
• ADS holders waive their right to a jury trial in any legal proceeding against the company or the depositary.

Risks

• The share register generally provides limited, or no, information regarding the ultimate beneficial owners of the company's ordinary shares.
• ADS holders are not treated as shareholders and their names will not be entered in the company's share register.
• The depositary may amend the deposit agreement without the consent of ADS holders, but must provide 30 days' notice for modifications that materially prejudice their rights.
• The depositary may terminate the deposit agreement with 30 days' notice to ADS holders.
• The deposit agreement limits the obligations and liabilities of the company and the depositary.
• ADS holders are responsible for taxes and governmental charges on ADSs and the underlying securities.
• ADS holders waive their right to a jury trial in any legal proceeding against the company or the depositary.

Industry Context

This document provides a detailed overview of the legal and structural framework for Mereo BioPharma Group plc's securities, which is essential for investors to understand the rights and obligations associated with owning the company's shares or ADSs. It also highlights the company's compliance with U.K. and U.S. regulations, which is crucial for maintaining investor confidence and market integrity.

Comparison to Industry Standards

• The structure of Mereo BioPharma Group plc's share capital, with ordinary shares represented by ADSs, is a common practice for international companies seeking to access U.S. capital markets, similar to companies like AstraZeneca and GlaxoSmithKline.
• The detailed description of shareholder rights, including voting rights, dividend entitlements, and preemptive rights, is consistent with standard corporate governance practices in the U.K., comparable to companies listed on the London Stock Exchange.
• The provisions for share transfers, shareholder meetings, and director appointments are in line with the requirements of the U.K. Companies Act 2006, similar to other U.K.-incorporated public companies.
• The discussion of takeover provisions and minority shareholder rights reflects the legal framework in the U.K., which is similar to other European jurisdictions but differs from U.S. corporate law.
• The description of the deposit agreement and the rights of ADS holders is standard for companies with ADSs listed on U.S. exchanges, comparable to companies like Novartis and Roche.
• The limitations on liability and the waiver of jury trial provisions in the deposit agreement are common in agreements between U.S. depositaries and foreign companies, similar to those of other international companies listed on U.S. exchanges.

Stakeholder Impact

• Shareholders are provided with a clear understanding of their rights and obligations.
• ADS holders are informed about the mechanisms for exercising their rights and receiving distributions.
• Potential investors are given a detailed overview of the company's securities structure and governance.
• The company's compliance with U.K. and U.S. regulations is highlighted, which is important for maintaining investor confidence.

Key Dates

Keywords

American Depositary Shares, Ordinary Shares, Securities Exchange Act, Share Register, Preemptive Rights, Articles of Association, Voting Rights, Dividends, Change of Control, Liquidation, Share Capital, Share Transfer, Shareholder Meetings, Directors, Takeover, Sell Out, Disclosure of Interest, Purchase of Own Shares, Distributions, City Code, Exchange Controls, American Depository Shares, Depositary, Custodian, Deposit Agreement, ADS Holder Rights, Dividends, Distributions, Redemption, Voting Rights, Fees and Charges, Amendments, Termination, Books of Depositary, Limitations on Liabilities, Taxes, Foreign Currency Conversion, Governing Law, Waiver of Jury Trial